Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01895673
Other study ID # NL43058.000.13
Secondary ID
Status Completed
Phase N/A
First received June 20, 2013
Last updated December 14, 2016
Start date June 2013
Est. completion date June 2016

Study information

Verified date December 2016
Source VU University Medical Center
Contact n/a
Is FDA regulated No
Health authority Netherlands: Medical Ethics Review Committee (METC)
Study type Observational

Clinical Trial Summary

The primary objective of this study is to evaluate the ability of PET-MRI and to detect a local site recurrence during the first year of follow-up after RFA or MWA of colorectal liver metastases (CRLM) as compared with contrast enhanced (ce) CT and PET-CT. Standard reference will be clear focal uptake in the rim of the lesion on PET-CT, possibly in combination with histology (when available) or clinical follow-up.

Secondary outcomes are the inter-observer variability, the ability to diagnose new intrahepatic lesions and in what way PET-MRI is able to influence future treatment compared to PET-CT and ceCT. The patients satisfaction concerning the PET-MRI will be examined with a questionnaire.


Description:

All included patients will routinely undergo follow-up with 3 monthly ceCT of the liver and PET-CT in the first year after RFA/MWA of CRLM according to standard of care in our hospital. Patients are asked to undergo an additional PET-MRI of the liver on the same day in the first year (in total 4 scans). The PET-MRI is obtained before the PET-CT. The 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose (FDG) used for PET-CT and PET-MRI are alike and one injection is sufficient. The PET-CT has to be made within 150 minutes after FDG injection. Anonymous PET-MRI results are independently reviewed by 2 experienced radiologists and 2 nuclear medicine physicians twice, with a time-interval of at least two weeks between the first and second review. Based on these results, treatment decisions will be compared for any change in decision making.

The evaluate inter-observer variability we will ask the two nuclear medicine physicians and two radiologist to assess all results and score local and intrahepatic tumor progression. Results of the first and second evaluation will be compared to determine inter observer agreement using Cohen's Kappa. Local recurrence and new lesions will be scored on a separate form with standard criteria.

The reports on LSR will be scored as follows:

- Normal: when the reviewer is sure that no tumor recurrence is present in the ablation zone.

- Probably benign: FDG is enhanced, but compatible with post-ablation inflammation or rim-like characteristics on MRI images (not focal!)

- Equivocal: there is doubt whether the enhanced FDG, CT- or MRI features are due to tumor recurrence or inflammation

- Probably malign: when the reviewer is sure about local recurrence in the ablation zone. Size and location will also be reported.

The reports on new intrahepatic lesions will be scored as follows:

- Normal: no new intrahepatic disease outside 1cm of the ablation zone

- Equivocal: doubt about the malignant origin of a lesion

- Probably malign: new intrahepatic tumor not within 1cm of the ablation zone, including size and location.

The results of all scans by the reviewers, in the way as described above, will be compared to each other to determine the inter-observer variability using Cohen's Kappa.

A questionnaire with 7 questions is completed at the end of one year follow-up to determine patients experience with PET-MRI and PET-CT.

The questions will be in Dutch, but are translated below for this purpose. Patients can answer on a scale 1-5 and n/a.

- The PET-MRI was less burdensome than PET-CT

- The PET-MRI was more bothersome than I expected

- PET-MRI is more comfortable than PET-CT

- If I could choose, I would rather undergo PET-MRI than PET-CT

- The noise of the PET-MRI was annoying

- The fact that PET-MRI takes longer than PET-CT isn't an issue for me

- I would rather undergo a PET-MRI than a PET-CT if results are proven to be equal


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date June 2016
Est. primary completion date June 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histological or cytological documentation of primary colorectal tumor

- Radiological or histological prove of one or more CRLM or radiological proof of a LSR after previous RFA/MWA treatment for CRLM

- CRLM or LSR treated with RFA/MWA or RFA/MWA in combination with resection

- Follow-up imaging performed in Free University (VU) University Medical Center

- Age ³ 18 years

- Life expectancy of at least 1 year

- estimated glomerular filtration rate (eGFR) > 60 or hydration according to protocol before scanning

- Written informed consent.

Exclusion Criteria:

- cirrhosis or steatosis of the liver

- Chemotherapy = 6 weeks before scanning (during the entire study)

- Pregnant or breast-feeding subjects

- Allergy to contrast media

- Patients developing recurrent intrahepatic disease that require resection of the ablated lesion

- eGFR < 60, unless hydration according to protocol is possible

- General exclusion criteria to undergo MRI

1. claustrophobia

2. intracranial clips

3. any implanted stimulation device (eg. internal cardioverter defibrillator/pacemaker, cochlear implant)

4. intra-ocular metal splinters or metal clips

5. Metal artificial heart valve

6. Bone prosthesis < 6 weeks

7. inability to lie still for 30 minutes

8. orthopnea

9. intestinal video capsule

10. Metal intra auricular prosthesis

all other prosthesis or piercings should be removed.

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Intervention

Other:
Gadolinium
All patients will undergo PET-MRI additional to the PET-CT they routinely undergo. All patients will be administered Gadolinium for the PET-MRI scan. This is an extra intervention than they would normally undergo.

Locations

Country Name City State
Netherlands VU University Medical Centre Amsterdam North-Holland

Sponsors (1)

Lead Sponsor Collaborator
dr. M.P. van den Tol MD PhD

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Local site recurrence (LSR) detection The primary objective of this study is to evaluate the ability of PET-MRI and diffusion and contrast enhanced MRI to detect LSR during the first year of follow-up after RFA treatment of CRLM as compared with ceCT and PET-CT. Standard reference will be clear focal uptake in the rim of the lesion on PET-CT, possibly in combination with histology (when available) or clinical follow-up. 1 year No
Secondary Detection new intrahepatic lesions the ability of PET-MRI to diagnose smaller new intrahepatic lesions than PET-CT and ceCT 1 year No
Secondary inter-observer variability Hard copy data sets of all PET-MRI and PET-CT scans, with no patient information, random order, independently reviewed by 2 experienced radiologists and 2 nuclear medicine physicians twice (reviewers blinded to the images and results of the other imaging modalities and blinded to the final outcome of patients), with a time-interval of at least two weeks between the first and second review. These scans are scored on a standardized form (explained in the section 'detailed description'). The outcomes between the different reviewers of the same scan are noted and compared to each other. Inter observer variability is determined using Cohen's Kappa. 1 year No
Secondary Influence on decision making in what way PET-MRI is able to change future treatment compared to PET-CT and ceCT 1 year No
Secondary Patients experience with PET-CT and PET-MRI A questionnaire with 7 questions is completed at the end of one year follow-up to determine patients experience with PET-MRI and PET-CT. This is done to get an idea of the possible objections and wishes of all patients. Results will be described.
The questions will be in Dutch, but are translated below for this purpose. Patients can answer on a scale 1-5 and n/a.
The PET-MRI was less burdensome than PET-CT
The PET-MRI was more bothersome than I expected
PET-MRI is more comfortable than PET-CT
If I could choose, I would rather undergo PET-MRI than PET-CT
The noise of the PET-MRI was annoying
The fact that PET-MRI takes longer than PET-CT isn't an issue for me
I would rather undergo a PET-MRI than a PET-CT if results are proven to be equal
end of one year follow-up No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03651154 - Hypovolemic Phlebotomy to Reduce Blood Transfusions in Major Hepatic Resections N/A
Not yet recruiting NCT03592550 - The eValuation of Image Guidance of Stereotactic Body Radiotherapy Using Ultrasound: Assessment in Liver
Not yet recruiting NCT02521129 - A New Track Ablation Device for Liver Biopsy: A Feasibility Study Phase 1/Phase 2
Not yet recruiting NCT02168608 - Remote Ischemia Precondition (RIPC) for Hepatic Protection in Patients Undergoing Hepatectomy N/A
Enrolling by invitation NCT01465425 - Extracolonic Findings on Computed Tomography (CT) Colonography
Active, not recruiting NCT01177007 - Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors Phase 2
Completed NCT00788697 - SonoVue®-Enhanced Ultrasound Versus Unenhanced US for Focal Liver Lesion Characterization Phase 3
Recruiting NCT01564810 - Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer Phase 4
Completed NCT00094003 - Study of NS-9 in Patients With Liver Metastases Phase 1
Terminated NCT00051532 - Seocalcitol Versus Placebo in Advanced Hepatocellular Carcinoma N/A
Completed NCT00001587 - A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver Phase 1
Completed NCT00222664 - Qidong Hepatitis B Intervention Study Phase 4
Recruiting NCT04518852 - TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC Phase 2
Completed NCT03289273 - Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)
Terminated NCT03349255 - Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma Phase 1
Recruiting NCT05068180 - Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients Phase 4
Recruiting NCT03715517 - Spinal Anesthesia For Enhanced Recovery After Liver Surgery N/A
Terminated NCT03685591 - PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors Phase 1
Terminated NCT01744054 - Microsphere Localization Using PET/MRI or PET/CT in Patients Following Radioembolization Phase 1
Active, not recruiting NCT02969096 - Clinical Study of Targeted Cryoablation Therapy in the Treatment of Hepatic Carcinoma Phase 2